Stay updated with breaking news from Frederik Marm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The addition of atezolizumab to bevacizumab and chemotherapy did not significantly improve overall survival or progression-free survival in patients with recurrent ovarian cancer.
Sacituzumab govitecan-hziy displayed a manageable safety profile consistent with previous reports in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, irrespective of UGT1A1 status, according to a safety analysis of the phase 3 TROPiCS-02 trial.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.